Xintela obtains US patent for stem cell treatment

06 December 2022 - 15:56

Xintela announces that the US patent office USPTO has today approved the company’s patent application for treatment of musculoskeletal diseases using Xintela’s stem cell products.

The USPTO today issued Xintela's patent US 11,517,593 covering stem cell treatment of musculoskeletal diseases including osteoarthritis and other degenerative joint diseases as well as treatment of traumatic joint injuries including damage of articular cartilage, bone, tendons and ligaments. Xintela's patented stem cell treatment consists of integrin α10β1-selected mesenchymal stem cells for both humans (XSTEM®), horses (EQSTEM®) and other animals. The patent is valid until the year 2039.

“This newly approved US patent will together with our previously approved stem cell product patents in Europe and several other countries, be key value driver in our discussions with potential partners and licensees. Our patents secure the continued development and commercialization of XSTEM and our veterinary stem cell products on important markets for many years to come”, says Xintela's CEO Evy Lundgren-Åkerlund.

Provided by: MFN
Nasdaq First North GM Stockholm (Sweden)
Xintela AB
Xintela is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More